In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Women’s Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Director of the Preventive Cardiology Clinic at Intermountain Medical Center in Utah. Together, they explore the latest advancements in LDL cholesterol management and discuss how clinicians can optimize risk assessment, treatment strategies, and patient adherence to improve cardiovascular outcomes. From discussing the new AHA PREVENT calculator to strategies for overcoming statin intolerance and emerging lipid-lowering therapies, this podcast provides practical insights into treating and preventing cardiovascular disease in 2025 – in just 30 minutes! 🎧 Listen Now to stay ahead in lipid management and help patients achieve better heart health. This activity has been approved for AMA PRA Category 1 Credit(s)™. After listening to the podcast discussion, go to Boston University Chobanian & Avedisian School of Medicine’s website: Cholesterol Conversations: Mastering LDL Management in 2025 | Chobanian & Avedisian School of Medicine/CCE. Scroll down for more information about CME/CPE credits. 💡 For more educational content on LDL cholesterol management, visit: Vasculearn Network Podcast Chapters: 1. Introduction & Overview (00:06 - 01:18) 2. Why is LDL Important? (01:18 - 03:47) 3. Risk Assessment & Screening Tools (03:47 - 08:39) 4. Special Risk Considerations (08:39 - 10:55) 5. Lipoprotein(a) & Additional Biomarkers (10:55 - 12:05) 6. Treatment Options: Statins & Beyond (12:05 - 17:24) 7. Overcoming Statin Intolerance (17:24 - 21:37) 8. Barriers to Treatment & Access Issues (21:37 - 25:00) 9. Future Directions & Emerging Therapies (25:00 - 28:23) 10. Final Takeaways (28:23 - 29:44) Learning Objectives At the end of this activity, the learner should be better able to: Describe current recommendations for LDL-C screening Identify patients at increased cardiovascular disease risk based on LDL-C levels Describe indications for initiation of statin and nonstatin therapies Identify barriers to therapy initiation and options for resolution Devise evidence-based strategies for optimal lipid management in primary prevention populations Launch Date: 3/31/2025 Expiration Date: 3/30/2026 Joint Accreditation In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician CME Hours Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Contact Hours: 0.5, all of which are eligible for pharmacology credits. Pharmacist Contact Hours This activity is approved for 0.5 CPE credit(s) under the ACPE universal activity number JA0000185-9999-25-024-H01-P. The activity is available for credit claiming through March 30, 2026. Speakers Disclosures Dr. Heather Johnson, MD, MS Course Director Disclosures: Dr. Johnson is a consultant for Amgen, Medtronic and Novartis. She is a consultant and a speaker for Esperion. Viet Le, DMSc, MPAS, PA-C Podcast Speaker Disclosures: Dr. Le is on the advisory board for Amarin, Amgen, Bayer, Idorsia, Lexicon, Merck, Novartis and Pfizer. He also receives grant research support from Johnson & Johnson and Janssen, Kardi and AliveCor and Novartis. Off-Label Discussion: will not be included. Accreditor Disclosures The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies: Michael Burk, BS – Operations Manager; Deborah Whalen, APRN, MS, MBA - CNE Accreditation Reviewer. John Fanikos, Rph, MBA Pharmacy Advisor Disclosures: Dr. Fanikos is a consultant for Anthos Therapeutics. He is also a speaker and consultant for AstraZeneca and Pfizer. Boston University Chobanian & Avedisian School of Medicine Disclosure Policy Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to ...
Show More
Show Less
Mar 30 202530 mins
19 mins
21 mins